Your browser doesn't support javascript.
loading
Locomotor activity and tissue levels following acute administration of lambda- and gamma-cyhalothrin in rats.
Moser, Virginia C; Liu, Zhiwei; Schlosser, Christopher; Spanogle, Terri L; Chandrasekaran, Appavu; McDaniel, Katherine L.
Afiliação
  • Moser VC; Toxicity Assessment Division, National Health Effects and Environmental Research Laboratory, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, USA. Electronic address: Moser.ginger@epa.gov.
  • Liu Z; FMC Corporation, 701 Princeton South Corporate Center, Ewing, NJ, USA.
  • Schlosser C; Health Effects Division, Office of Pesticide Programs, Office of Chemical Safety and Pollution Prevention, US Environmental Protection Agency, Washington, DC, USA.
  • Spanogle TL; FMC Corporation, 701 Princeton South Corporate Center, Ewing, NJ, USA.
  • Chandrasekaran A; FMC Corporation, 701 Princeton South Corporate Center, Ewing, NJ, USA.
  • McDaniel KL; Toxicity Assessment Division, National Health Effects and Environmental Research Laboratory, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, USA.
Toxicol Appl Pharmacol ; 313: 97-103, 2016 Dec 15.
Article em En | MEDLINE | ID: mdl-27794438
ABSTRACT
Pyrethroids produce neurotoxicity that depends, in part, on the chemical structure. Common behavioral effects include locomotor activity changes and specific toxic syndromes (types I and II). In general these neurobehavioral effects correlate well with peak internal dose metrics. Products of cyhalothrin, a type II pyrethroid, include mixtures of isomers (e.g., λ-cyhalothrin) as well as enriched active isomers (e.g., γ-cyhalothrin). We measured acute changes in locomotor activity in adult male rats and directly correlated these changes to peak brain and plasma concentrations of λ- and γ-cyhalothrin using a within-subject design. One-hour locomotor activity studies were conducted 1.5h after oral gavage dosing, and immediately thereafter plasma and brains were collected for analyzing tissue levels using LC/MS/MS methods. Both isomers produced dose-related decreases in activity counts, and the effective dose range for γ-cyhalothrin was lower than for λ-cyhalothrin. Doses calculated to decrease activity by 50% were 2-fold lower for the γ-isomer (1.29mg/kg) compared to λ-cyhalothrin (2.65mg/kg). Salivation, typical of type II pyrethroids, was also observed at lower doses of γ-cyhalothrin. Administered dose correlated well with brain and plasma concentrations, which furthermore showed good correlations with activity changes. Brain and plasma levels were tightly correlated across doses. While γ-cyhalothrin was 2-fold more potent based on administered dose, the differences based on internal concentrations were less, with γ-cyhalothrin being 1.3- to 1.6-fold more potent than λ-cyhalothrin. These potency differences are consistent with the purity of the λ-isomer (approximately 43%) compared to the enriched isomer γ-cyhalothrin (approximately 98%). Thus, administered dose as well as differences in cyhalothrin isomers is a good predictor of behavioral effects.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piretrinas / Locomoção / Nitrilas Limite: Animals Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piretrinas / Locomoção / Nitrilas Limite: Animals Idioma: En Ano de publicação: 2016 Tipo de documento: Article